CD274 and gastric cancer: Based on the results of a phase II study [12], pembrolizumab (an anti-PD-1 ICI) has been approved by the food and drug administration (FDA) for the treatment of patients with recurrent locally advanced or metastatic GC whose tumours express PD-L1.